SecProbe.io

CORRESP
1
filename1.htm

BioQuest
Corp.

3700
Campus Drive, Suite 206

Newport
Beach, CA 92660

Phone:
(714) 978-4425

Celeste
Murphy

Division
of Corporation Finance

Office
of Life Sciences

United
States Securities and Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

    Re:

    BioQuest
    Corp.

    Offering
    Statement on Form 1-A

    Filed:
    October 21, 2020

    File
    No. 024-11151

November
24, 2020

Dear
Ms. Murphy,

This
letter sets forth the request of BioQuest Corp., (“BQST” or the “Company”) for Qualification of its Regulation
A Offering.

Kindly
be advised that BioQuest Corp. (the “Company”) requests that its Regulation A offering be qualified on Wednesday,
November 25, 2020 at 3pm or as soon as practical thereafter.

In
connection with the foregoing request, the Company hereby confirms and acknowledges that:

    1.
    should
    the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission
    from taking any action with respect to the filing;

    2.
    the
    action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve
    the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

    3.
    the
    Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any
    person under the federal securities laws of the United States.

We
trust the foregoing is in order.

If
you have any questions or require any additional information with respect to the above, please do not hesitate to contact me at
(714) 978-4425 or Andrew Coldicutt of the Law Office of Andrew Coldicutt at (619) 228-4970. Thank you for your attention to this
matter.

    BioQuest Corp.

    /s/ Thomas Hemingway

    Name:
     Thomas Hemingway

    Title:
    Chief Executive Officer, Director